Not your time zone? Please find the conversion here.
The assessment of immunogenicity of biological protein drugs is a key component in drug development. A basic knowledge in immunology is a prerequisite for understanding the principles of adverse, unwanted immune responses. In addition, emerging technologies are making analytical and clinical data interpretation more challenging. Likewise, the comparative immunogenicity analysis of an innovative therapeutic and biosimilar needs to be addressed closely.
Submit a question for the live Q&A session by tweeting us @BioanalysisZone & using #BZwebinars
What will you learn?
- Basic immunology
- Principles of immunogenicity testing
- Challenges in cut-point determination
- Immunogenicity of biosimilars
Who may this interest?
People interested in immunology:
- Quality Managers
Dr. Arno Kromminga
European Chief Strategy Officer
Dr. Kromminga is an esteemed senior expert in autoimmunity, allergy, and other immune mediated diseases, including assay development and clinical interpretation of laboratory parameters. He is also a co-founder and board member of the European Immunogenicity Platform (EIP), and member of multiple scientific societies including the American Association of Pharmaceutical Scientists (AAPS), German Society of Immunology (DGfI), German Society of Clinical Chemistry and Laboratory Medicine (DGKL). As a world-leading authority in the area of immunogenicity, he is invited to speak at numerous international scientific conferences and has authored multiple peer-reviewed scientific publications in journals and text books.
For a full list of other webinars available on Bioanalysis Zone please see here.